|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
|
|
|
|
€ 1 400,00 |
Editeur
: |
ZZZ - Biovista |
Langue
: |
Anglais |
Date de publication : |
Décembre 2000 |
Taille du document : |
150 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (3) |
|
|
|
| 41 pages | Août 2006 | Anglais
|
|
|
| Main
focus: |
jewellery,watch,watches,clocks,jewelry,jewel,...
|
| Research
focus: |
market size and estimates,market segmentation, |
| Geographic
focus: |
india,usa,switzerland,france,malaysia,netherlands |
| |
|
|
|
|
| 48 pages | Décembre 2006 | Anglais
|
|
|
| Main
focus: |
watch,information technology
|
| Research
focus: |
market outlook,market definition, |
| Geographic
focus: |
usa,canada,united kingdom,france,brazil,croatia,... |
| |
|
|
|
|
| 77 pages | Juin 2005 | Anglais
|
|
|
| Main
focus: |
watch,watches,clocks,luxury watches,luxury watch,...
|
| Research
focus: |
market size and estimates,competition analysis, |
| Geographic
focus: |
singapore,malaysia,usa,hong kong,indonesia,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Biotech Industry Potential: Emerging Markets & Trends 15 pages | Novembre 2002 |
The global biotech industry is comprised of 4,284 companies in 25 nations. The 622 public companies generated revenues of $35 billion, spent $16 billion in R&D and employed more than 188,000 people |
250,00 €
|
| |
| |
Strategies for Biogeneric Success 71 pages | Juin 2004 |
What will determine success? Development of biogeneric molecules for sale in the potentially highly lucrative US and Western European markets depends on the ability to answer three key questions |
1 500,00 €
|
| |
| |
Signal Transduction 170 pages | Décembre 2000 |
Novel drug targets are emerging from the elucidation of the molecular chain reactions that underlie the responses of cells to their environment. Signal transduction is the term describing the p |
1 400,00 €
|
| |
| |
03-011: The Market for Real-Time PCR Reagents & Instrumentation 180 pages | Avril 2003 |
Based on a detailed 52-question survey of 406 scientists who currently perform qPCR, this report describes their research interests and specific applications |
640,00 €
|
| |
| |
03-052A: Protein Purification Systems: Market Opportunities for Research Product Suppliers 163 pages | Octobre 2003 |
This report will help suppliers exploit opportunities to differentiate themselves from their competitors and develop more advanced protein purification tools |
960,00 €
|
| |
| |
03-038: Clinical Proteomics: A First-Glance Market Report 96 pages | Septembre 2003 |
his First-Glance Market Report identifies the research objectives, methodologies, assay parameters and technological limitations that are currently associated with disease-based protein-profiling stud |
400,00 €
|
| |
| |
Biochips IRCD pages | Juillet 2001 |
The notion of a cheap and reliable computer chip look-alike that performs thousands of biological reactions is a very attractive one, because it miniaturizes, automates and accelerates otherwise cumbe |
1 200,00 €
|
| |
| |
Pharmacogenomics IRCD pages | Juillet 2001 |
The Human Genome Project and numerous corporate and academic human gene sequencing efforts have revealed, among others, that genes exist in the population in numerous mutated forms, some of which are |
1 200,00 €
|
| |
| |
Antisense Therapy: Technical Aspects and Commercial Opportunities 334 pages | Mars 2000 |
Antisense therapy interferes with the expression of disease-causing proteins, thus offering a direct and selective intervention in the disease process. Besides the well known oligonucleotides ( |
955,00 €
|
| |
| |
Arthritis Drug Discovery IRCD pages | Juin 2001 |
Arthritis (from the Greek for joint) is a chronic multi-factorial disease of the joints, induced when the immune system attacks and begins degrading the joints. The disease knows no racial boun |
1 026,17 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
Identified by The Economist (*) as the industry to watch for 1997 in the chemicals  
  sector, Combinatorics (also known as combinatorial chemistry) is an emerging  
  platform technology that uses test tube evolution to rapidly generate libraries  
  of new drug candidates from which those with the right properties are selected.  
 
 
  Reducing substantially research costs, the scope and reach of this technology  
  which represents an industry worth well over $2 billion, is enormous. (*)
 
  The Economist: The World in 1997, page 94 The Industry Review and Company Database  
  on Combinatorics has the following aims:
 
  · to introduce and describe the essential elements of Combinatorics as  
  a platform technology
 
  · to introduce and describe the essential elements of Combinatorics as  
  a platform business
 
  · to provide the most comprehensive listing available of companies using  
  Combinatorics
 
  · to serve as a business networking node in the Combinatorics arena
|
|
Executive Summary
Aims and Scope
IRCD Structure
PART 1: TECHNOLOGY
Combinatorics Technology
Definitions
Process description
Combinatorics for new drugs
Library synthesis approaches
Combinatorics information management
PART 2: BUSINESS USERS AND MARKET
Combinatorics Commercialization
Financial emergence of Combinatorics
Raising capital for Combinatorics
Tool vs. target
Strategic developments
Corporate activity in 1998
Synopsis of notable events in 1998
Descriptions of 1998's corporate activities
Discussion of 1998's corporate activities
Combinatorics consortia
Intellectual property issues
Clinical efforts
Future financing trends
Reference list
PART 3: COMPANIES
Methodology
Concise Company Listing
Extended Company Listing
PART 4: PATENTS
Methodology
Concise Patent Listing
Extended Patent Listing
|
|
|
PPLSEN
|
|
|
|
|